BriaCell Therapeutics Corp. (NASDAQ:BCTX) to Post Q1 2025 Earnings of ($0.30) Per Share, HC Wainwright Forecasts

BriaCell Therapeutics Corp. (NASDAQ:BCTX) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of BriaCell Therapeutics in a research note issued on Thursday, October 3rd. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings of ($0.30) per share for the quarter. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for BriaCell Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BriaCell Therapeutics’ Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.19) EPS and Q4 2025 earnings at ($0.17) EPS.

BriaCell Therapeutics Trading Up 2.5 %

BCTX stock opened at $0.98 on Friday. The stock has a 50-day moving average price of $0.71 and a 200-day moving average price of $1.38. BriaCell Therapeutics has a 1-year low of $0.46 and a 1-year high of $6.16. The firm has a market cap of $18.00 million, a PE ratio of -0.79 and a beta of 1.34.

Hedge Funds Weigh In On BriaCell Therapeutics

An institutional investor recently raised its position in BriaCell Therapeutics stock. Onyx Bridge Wealth Group LLC boosted its position in BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 66.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 50,000 shares of the company’s stock after purchasing an additional 20,000 shares during the period. Onyx Bridge Wealth Group LLC owned about 0.31% of BriaCell Therapeutics worth $143,000 as of its most recent SEC filing. 15.42% of the stock is currently owned by institutional investors.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.